Bank of New York Mellon Corp
BankPosition in SABS — SAB Biotherapeutics, Inc.
CIK 1390777
NEW YORK, NY
Position in SABS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$420,602
New position
Shares Held
107,847
first reported quarter
Ownership
0.119%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 86 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 87%
Shared 0%
None 13%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bank of New York Mellon Corp holds $4,845,290,998 across 311 Biotechnology names. SABS ranks #253 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,672,623 | $830,842,010 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
758,492 | $472,950,091 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,578,013 | $380,253,782 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
492,071 | $148,128,128 | |
| 5 | INSM |
INSMED Inc
|
1,312,756 | $139,966,036 | |
| 6 | MRNA |
Moderna, Inc.
|
1,701,675 | $119,168,293 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
601,056 | $112,565,759 | |
| 8 | INCY |
Incyte Corp
|
972,825 | $110,279,435 |
All Filings in SABS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $420,602 | 107,847 | Shares | Defined | 2026-08-06 | |
| No filing history on record for this holder in this stock. | ||||||